

Harry Sokol

Harry Sokol is a Professor in the Gastroenterology department of Saint-Antoine Hospital (APHP, Sorbonne Université, Paris, France), the co-director of the Microbiota, Gut & Inflammation team (INSERM CRSA UMRS 938, Sorbonne Université, Paris), and group leader in Micalis institute (INRAE), and coordinator of the Gut, Liver & Microbiome Research (GLIMMER) Hospital-University Federation. He is an internationally recognized expert in the inflammatory bowel disease (IBD) and gut microbiota fields, and he has published more than 400 papers on these topics in major journals. He is the current president of the French group of Fecal Microbiota Transplantation, and the head of the APHP Fecal Microbiota Transplantation Center. His work on the role of gut microbiota in IBD pathogenesis led to landmark papers, including identifying the pivotal role of the commensal bacteria *Faecalibacterium prausnitzii* in gut homeostasis and IBD. Currently, his work focuses on deciphering gut microbiota–host interactions in health and disease to better understand their role in pathogenesis and develop innovative treatments. Harry Sokol received two grants from the European Research Council (ERC) in 2016 and 2022, and he is a member of the International Organization for the Study of IBD (IOIBD). Since 2020, he is recognized as a Highly Cited Researcher (Clarivate, Web of Science). Harry Sokol is currently Associate Editor for Gastroenterology. Harry Sokol co-founded Exeliom biosciences (<https://www.exeliombio.com/>).